Next Article in Journal
Raman Spectral Signatures of Serum-Derived Extracellular Vesicle-Enriched Isolates May Support the Diagnosis of CNS Tumors
Next Article in Special Issue
TRAF6 Phosphorylation Prevents Its Autophagic Degradation and Re-Shapes LPS-Triggered Signaling Networks
Previous Article in Journal
Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients
Previous Article in Special Issue
Targeting NF-κB Signaling for Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 6
10.3390/cancers13061411
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis

by
Xin Li
and
Yinling Hu
*
Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(6), 1411; https://doi.org/10.3390/cancers13061411
Submission received: 28 January 2021 / Revised: 8 March 2021 / Accepted: 15 March 2021 / Published: 19 March 2021
(This article belongs to the Special Issue NF-kB Signaling in Cellular Responses to Threats, Cancer Development and Therapy)
Browse Figure
Versions Notes

Abstract

:

Simple Summary

CHUK/IKKα has emerged as a novel tumor suppressor in several organs of humans and mice. In general, activation of NF-κB promotes inflammation and tumorigenesis. IKKα reduction stimulates inflammatory responses including NF-κB’s targets and NF-κB-independent pathways for tumor promotion. Specific phenomena from genetically-modified mice and human TCGA database show the crosstalk between IKKα and NF-κB although their nature paths for normal organ development and the disease and cancer pathogenesis remains largely under investigation. In this review, we focus on the interplay between IKKα and NF-κB signaling during carcinogenesis. A better understanding of their relationship will provide insight into therapeutic targets of cancer.

Abstract

Studies analyzing human cancer genome sequences and genetically modified mouse models have extensively expanded our understanding of human tumorigenesis, even challenging or reversing the dogma of certain genes as originally characterized by in vitro studies. Inhibitor-κB kinase α (IKKα), which is encoded by the conserved helix-loop-helix ubiquitous kinase (CHUK) gene, is first identified as a serine/threonine protein kinase in the inhibitor-κB kinase complex (IKK), which is composed of IKKα, IKKβ, and IKKγ (NEMO). IKK phosphorylates serine residues 32 and 36 of IκBα, a nuclear factor-κB (NF-κB) inhibitor, to induce IκBα protein degradation, resulting in the nuclear translocation of NF-κB dimers that function as transcriptional factors to regulate immunity, infection, lymphoid organ/cell development, cell death/growth, and tumorigenesis. NF-κB and IKK are broadly and differentially expressed in the cells of our body. For a long time, the idea that the IKK complex acts as a direct upstream activator of NF-κB in carcinogenesis has been predominately accepted in the field. Surprisingly, IKKα has emerged as a novel suppressor for skin, lung, esophageal, and nasopharyngeal squamous cell carcinoma, as well as lung and pancreatic adenocarcinoma (ADC). Thus, Ikkα loss is a tumor driver in mice. On the other hand, lacking the RANKL/RANK/IKKα pathway impairs mammary gland development and attenuates oncogene- and chemical carcinogen-induced breast and prostate tumorigenesis and metastasis. In general, NF-κB activation leads one of the major inflammatory pathways and stimulates tumorigenesis. Since IKKα and NF-κB play significant roles in human health, revealing the interplay between them greatly benefits the diagnosis, treatment, and prevention of human cancer. In this review, we discuss the intriguing attribution of NF-κB to CHUK/IKKα-involved carcinogenesis.

1. Introduction

Five NF-κB transcriptional factors, including RelA (p65), RelB, c-Rel, NF-κB1 (p50), and NF-κB2 (p52), are differentially expressed in a wide range of cell types and execute their physiological functions through the compositions of their homodimers or heterodimers (Figure 1) [1]. Studies using genetically modified mouse models show that the biological roles of these transcription factors partially overlap [2]. These NF-κB components are classified into the canonical and non-canonical NF-κB pathways, as initiated by their upstream regulators [3,4]. In the canonical signaling (Figure 1), the NF-κB inhibitor IκBα interacts with NF-κB p65/p50 dimers that mask the nuclear localization signal of NF-κB, thereby blocking NF-κB’s nuclear translocation from cytosol to nucleus and inactivating NF-κB. In the non-canonical signaling, an NF-κB-inducing kinase (NIK) activates IKKα, which then phosphorylates and then cleaves the p100 to generate p52, resulting in RelB/p52 dimer nuclear translocation [4,5]. The activated NF-κB functions as a transcriptional factor by binding to the DNA consensus sequences on the regulatory elements of the target genes. IKKα and IKKβ, which are highly conserved protein kinases containing a protein kinase domain, a leucine zipper motif, and a helix-loop-helix motif, are catalytical subunits [6,7,8,9,10]. IKKγ is a regulatory subunit in the IKK complex. There is an IKKγ binding motif at the end of the C-terminus of IKKα and IKKβ. Following activation of the receptors, the activated IKK stimulates canonical and non-canonical NF-κB activation and transduces signals from external cells to the cellular nucleus. These IKK subunits are not functionally redundant because Ikkα−/−, Ikkβ−/−, or Ikkγ−/− mice display severe phenotypes (Table 1), although Ikkβ−/−, Ikkγ−/−, and p65−/− mice show a similar phenotype of embryonic lethality from hemorrhage mediated by liver cell death and are rescued by Tnfr1 deletion, which blocks cell death [11,12,13,14,15,16,17]. Ikkα−/− mice die within 15 minutes after birth due to water loss from severely impaired skin, and Tnfr1 deletion does not rescue them [18]. Thus, IKKα plays a distinct physiological function from IKKβ and IKKγ during embryonic development.
Following ligand stimulation, activated receptors on cell surfaces transduce signals from external cells to the cellular cytosol and nucleus, leading to the activation or suppression of specific pathways and events at various levels in the cells. TNFR family members, such as TNFR1/TNF, LTβR/LTβ, BAFFR/BAFF, CD40/CD40L, and RANK/RANKL, which are differentially expressed in a broad variety of specific cells, execute distinct biological activities and regulate tumorigenesis. In general, increased NF-κB activity promotes tumorigenesis. For example, defective RANKL/RANK/IKKα signaling impairs mammary gland development and damps oncogene-mediated breast carcinogenesis [34]. IKKα loss, meanwhile, promotes the development of cutaneous, lung, and esophageal squamous cell carcinomas (SCCs) and lung and pancreatic ADCs [19,22,23,35,36,37,38,39,40], which are associated with increased NF-κB related targets and inflammation. However, the way in which IKKα crosstalks with the NF-κB pathway remains to be fully elucidated. Here, we discuss the connections between IKKα and NF-κB activity in skin, lung, and esophageal SCCs; lung and pancreatic ADCs; and breast and prostate cancer.

2. IKKα, NF-κB, and Carcinogenesis

2.1. Squamous Cell Carcinoma

The surfaces of our bodies, some internal organs, and the interface of the tracts, which connect or are located inside organs, are covered by the epithelium, which is composed of a similar type of squamous or pseudo-squamous epithelial cells and protect these organs and our body. The basal cells of the squamous epithelium express keratin 5 (K5), K14, and p63 and are able to proliferate and differentiate in response to various stimuli, including growth factors, cytokines, chemokines, inflammatory irritants, and chemical carcinogens. These basal cells are also able to give rise to benign papilloma and malignant SCC. Deletions and reduction of CHUK, which encodes IKKα, reportedly promote SCC development in the skin, lungs, oral cavity, esophagus, and nasopharynx of humans [19,22,23,35,36,37,38,39,40].

2.1.1. Skin Diseases and Cutaneous SCC

IKKα activity in mouse embryonic development. The skin, which is made up of the epidermis and dermis, is the largest organ. The epidermis consists of undifferentiated to terminally differentiated keratinocytes (a type of squamous epithelial cells) that form the cornified layer and protects our bodies. Ikkα−/− newborns have a strikingly thick epidermis that lacks the terminally differentiated keratinocytes and has significantly increased numbers of K5/K14- and Ki67-positive cells. As a result, bodily fluid flows out of Ikkα−/− skin, which causes the mutant mice to die [11]. Reintroducing IKKα in vivo and in vitro rescues the undifferentiation defect in Ikkα−/− mouse keratinocytes and the mutant mice [41]. Meanwhile, the fetal liver is a major target for IKKβ, IKKγ, and p65 during embryonic development [14,15,17]; whereas LPS injection induces a comparable level of the IKK kinase activity in the liver of Ikkα−/− and wild-type (WT) newborn pups [11]. The 32 and 36 serine residues of IκBα are used as a kinase substrate, analyzed by an immunoprecipitated kinase assay with an anti-IKKγ antibody. Ikkα−/− embryonic fibroblasts remain at a similar or slightly decreased NF-κB and IKK activity level in response to TNFα or IL-1β stimulation compared to WT cells, as detected with an anti-IKKβ antibody immunoprecipitated kinase assay [11]. Of interest, an anti-IKKγ antibody immunoprecipitated kinase assay showed slightly higher kinase activity in Ikkα−/− fibroblasts than in WT cells in response to IL-1β but not TNFα stimulation [41]. In addition, the IKK kinase and NF-κB activities increase in response to these stimuli in primary cultured Ikkα−/− keratinocytes compared to WT. Collectively, IKKα deletion is not able to fully block the IKK kinase and NF-κB activities compared to IKKβ or IKKγ deletion, or else IKKα deletion elevates IKK/NF-κB activity, depending on cell type.
The importance of CHUK/IKKα in human embryonic development. A CHUK nonsense mutation that creates a stop code at amino acid 422 to generate a truncated and unstable protein, which in turn causes IKKα loss, is identified in an autosomal recessive lethal syndrome [29]. The appearance of the mutant human fetuses at 12 to 13 weeks old, which is characterized by multiple defects in the face, limbs, kidneys, heart, skull bones, and lungs, is similar to that of the Ikkα−/− newborn pups (Table 1). Thus, CHUK/IKKα is essential for human embryonic development. On the other hand, humans with a IKBKB gene mutation undergo the normal embryonic development but suffer severe bacterial, viral, and fungal infections after birth [30,31,32,33]. Thus, IKKα is required for human and mouse embryonic development independently of TNFR1, while IKKβ and IKKγ are essential for protecting liver cells of mouse embryos from apoptosis through a TNFR1-led NF-κB pathway (Table 1).
IKKα Transgene versus Ikkα gene deletionin skin inflammation and tumorigenesis. Of note, Tg-K5.mIκBα transgenic mice, in which there is a super suppressor mIκBα with mutations at amino acids 32 and 36 from serine to alanine, develop spontaneous skin SCCs associated with increased inflammation (Table 1) [20]. Ablation of the Tnfr1 gene abolishes skin inflammation and SCC in Tg-K5. mIκBα;Tnfr1−/− mice [21]. Thus, it has been suggested that decreased NF-κB activity promotes skin tumorigenesis. However, Tg-K5.IKKβ mice show epidermal hyperplasia and oral tumors (Table 1) [25,26], and Tg-EDL2.IKKβ mice that overexpress IKKβ in the esophageal epithelial cells also develop hyperplasia in the esophagus [27]. On the other hand, Tg-K5.IKKα mice develop normal skin and esophagus at one day and one year of age [24]. Thus, the role of IKK and NF-κB in skin homeostasis and tumorigenesis is intriguing.
Ikkα+/− mice, which look normal, develop twice as many papillomas and 10 times as many malignant SCCs than Ikkα+/+ mice in the chemical carcinogen–induced carcinogenesis setting [19] (Table 1). These Ikkα+/− SCCs lost the WT Ikkα allele, and IKK kinase activity is increased compared to Ikkα+/+ carcinomas, which is correlated with increased ERK activity, poorly differentiated cell features, and WT Ikkα allele loss [19], indicating that IKKα loss promotes the malignant conversion from papillomas to carcinomas. Moreover, the expression of IL-1α, TNFα, TGFα, EGF, amphiregulin, HB-EGF, FGF2, FGF3, and VEGFA is higher in Ikkα+/− skin than in Ikkα+/+ skin, treated with a chemical skin-tumor-promoter (inflammatory irritant). Although the chemical carcinogen stimulates IKKα expression in the normal skin and early benign tumors [19,42], the heterozygous Ikkα gene (Ikkα+/−) expresses a half dose of induced IKKα in response to stimuli compared to WT (Ikkα+/+), which attenuates IKKα anti-tumor activity. Thus, IKKα is a tumor suppressor with a haplo-insufficient feature.
To demonstrate whether IKKα loss induces spontaneous skin tumors, we ablated Ikkα with K5.Cre and found that Ikkαf/f;K5.Cre mice die within three weeks after birth [37] (Table 2). Furthermore, the inducible ablation of Ikkα in the basal keratinocytes or stem cells of adult Ikkαf/f mice by inducible K5.CreER or K15.CreRP1 with tamoxifen or RU486 results in spontaneous skin papillomas and SCCs [37]. Thus, IKKα deletion is a tumor driver. The tumor microenvironment modulates tumorigenesis. We have shown that inflammatory cytokines downregulate IKKα levels [23]. IKKα inactivation and increased macrophage numbers upregulate the expression of cytokines and chemokines, which are targets of NF-κB [43,44,45,46], and result in spontaneous lung SCCs, although the underlying mechanism requires further investigation.
On the other hand, IKKα overexpression inhibited chemical carcinogen–induced skin SCC metastasis or UVB-mediated skin carcinogenesis in transgenic Tg-Lori.IKKα or Tg-K5.IKKα mice, in which the IKKα cDNA is controlled by the loricrin promoter or the keratin 5 promoter [24,52]. Furthermore, the hyperproliferative epidermis lacking IKKα expressed increased IL-1, IL-6, and TNFα associated with increased macrophage infiltration. In contrast, overexpressed IKKα does not activate IKK kinase or NF-κB activity in the skin of Tg-K5.IKKα mice [53]; instead, it represses Ikkα deletion–mediated cytokine expression and macrophage infiltration in the skin of Ikkαf/f;K5.Cre;K5-IKKα mice. Overall, IKKα represses inducible NF-κB–related inflammation in skin.
Neonatal skin manifestations versus tumorigenesis. Intriguingly, all Ikkβf/f;K14.Cre, Ikkγf/f;K14.Cre, and Ikkαf/f;K5.Cre (and Ikkαf/f;K14.Cre) newborn pups specifically lacking either Ikkβ, Ikkγ, or Ikkα in skin keratinocytes look normal [37,47,48]. However, these mutant mice gradually develop severe skin inflammation and epidermal hyperplasia after three to four days and die within two to three weeks after birth (Table 2). Again, Tnfr1 deletion rescues the skin and death phenotypes of Ikkβf/f;K14.Cre and Ikkγf/f;K14.Cre mice but it does not do so for Ikkαf/f;K5.Cre and Ikkαf/f;K14.Cre mice [37,47,48]. In addition, the epidermal layer is thicker in newborn mice than in adult mice, and the newborn skin has shorter hair follicles than adult mouse skin. The microbiome is closely associated with hair follicles and skin [37]. Thus, it is possible that alterations in IKKβ, IKKγ, or IKKα expression alter microbiota, which may contribute to epidermal hyperplasia and skin inflammation phenotypes in Ikkβf/f;K14.Cre, Ikkγf/f;K14.Cre, and Ikkαf/f;K5.Cre neonatal mice. Furthermore, inducible ablation of either Ikkβ, Ikkγ, or Ikkα in the skin of adult mice may have less of an effect on skin microbiota than in neonatal skin. Of note, Iκbαf/f;K5.Cre and Iκbα−/− mice show severe skin inflammation, whereas p65(Rela)f/f;K5.Cre mice develop normally [28,50,54] (Table 2). Taken together, it remains largely unclear whether and how IKK and NF-κB are involved in maintaining microbiota-related skin homeostasis and tumorigenesis.
Although Tnfr1 knockout does not rescue Ikkαf/f;K5.Cre;Tnfr1−/− mice, the mutant skin highly express TNFα compared to WT [37]. Instead, EGFR reduction rescues a fraction of Ikkαf/f;K5.Cre;Egfr+/− mice characterized by hairlessness, suggesting that IKKα’s targets include EGFR during neonatal skin development. Inducible Ikkαf/f;K5.CreER and Ikkαf/f;K15.CreRP1 mice develop spontaneous skin tumor development, and treatment with GW2974, an EGFR inhibitor, prevents the tumorigenesis (Table 2). Inducible Ikkγ deletion in adult mice did not cause skin diseases, and inducible Ikkβ deletion induced skin inflammation in some mutant mice [48,49]. There are no skin tumors reported in mice with inducible Ikkβ or Ikkγ deletion in the skin. These analyses indicate that IKKα loss and reduction elevate the expression of NF-κB targets, such as TNFα and IL-1, which are correlated with skin inflammation and tumorigenesis. Furthermore, Tnfr1−/− and Tnfa−/− mice are resistant to chemical carcinogen–induced skin carcinogenesis compared to WT mice [55,56]. Although these cytokines, such as TNFα, are not required for mouse embryonic and skin development, these induced inflammatory cytokines can stimulate inflammation-associated carcinogenesis. Taken together, these results suggest that the different events take place at different stages of embryonic skin, neonatal skin, and skin tumor development. Many questions remain to be addressed.
Impaired central tolerance-mediated autoinflammation. The cause of skin inflammation and spontaneous tumors developed in Tg-K5.mIκBα mice remains a mystery, although Tnfr1 deletion rescues the skin phenotypes in Tg-K5.mIκBα mice [20,21]. Over the past several years, we have learned that RANK/RANKL, CD40/CD40L, LTβR/Ltβ, IKKα, NIK, and RelB are required to develop medullar thymic epithelial cells (mTECs) [23,57,58,59,60,61,62,63,64]. The autoimmune regulator, which is expressed in mTEC, regulates the expression of tissue restrict antigens and other regulators that maintain the thymic microenvironment, which helps delete autoreactive T cells within the thymus and establish central tolerance [65]. Kinase-dead IKKα (IKKα-KA/KA), in which a lysine is replaced by an alanine at amino acid 44, an ATP binding site within the protein kinase domain, attenuates NF-κB (p65/p50) activity in mTEC and severely impairs mTEC and central tolerance development in IkkαKA/KA mice (Table 2) [23]. The IKKβ and IKKγ levels in IkkαKA/KA mTEC are decreased compared to WT. Different thymic stromal cells express distinct keratins, and mTEC expresses K5 [23]. Reintroduction of Tg-K5.IKKα partially elevates p65/p50 activity, rescues mTEC development, and dampens autoimmune phenotypes in IkkαKA/KA;Tg-K5.IKKα mice compared to IkkαKA/KA mTEC and IkkαKA/KA mice. Therefore, a defect in IKKα and NF-κB pathways results in negative T-cell selection, central tolerance defects, and autoimmune diseases. IkkαKA/KA newborn mice look normal. After three months, the mutants start to show autoimmune phenotypes, and with increasing age, the phenotypes become worse.
To date, mice lacking Rank, Rankl, Cd40, Cd40l, Ltβr, Ltβ, or Nik develop autoimmunity, but none of these knockout mice develop spontaneous tumors [57,58,59,60]. Gradually decreased IKKα levels in epithelial cells are correlated with severe skin inflammation and tumorigenesis, as IkkαKA/KA mice age [23,66]. We demonstrated that the autoreactive CD4 T cells initiate the skin autoinflammatory phenotypes with increased macrophage and neutrophil numbers, inflammasome activity (NLRP3), uric acid levels, and expression of CCL2, CXCR2, CXCL1, and IL-1β in IkkαKA/KA skin compared to WT [66]. NLRP3 inhibition or CCL2/CXCR2 deletion rescued the skin phenotypes in the mutant mice. Although Tnfr1 deletion does not rescue the skin and death phenotypes in Ikkαf/f;K5.Cre mice [37], its knockout improves IkkαKA/KA skin phenotypes (unpublished data), suggesting that an overexpressed TNF/TNFR1 pathway may be involved in the skin phenotypes of adult IkkαKA/KA mice but is not a cause for Ikkα ablation-initiated embryonic and neonatal skin phenotypes.
Moreover, an overexpressed K5.IKKα transgene partially regulates mTEC and central tolerance development [23,67]. Most likely, the biological impact of the specific K5 promoter-driven transgenic gene is earlier than the function of the K5 promoter-driven Cre on the central tolerance establishment during embryonic thymus development because the specific Cre takes two steps and the transgenic gene only takes one step to execute its biological activities. Thus, Tg-K5.mIκBα mice may show autoinflammation-associated skin tumors because overexpressed mIκBα may downregulate NF-κB activity in mTEC [23], but IκBαf/f;K5.Cre mice may not develop the autoinflammatory phenotypes [50]. Furthermore, our unpublished finding showed that IKKα-KA/KA binds to IκBα more strongly than WT IKKα does. We then hypothesize that kinase-inactivated IKKα and unphosphorylated mIκBα enhance their interaction in the cytosol, which may ameliorate nuclear IKKα levels that regulate cell differentiation, proliferation, and tumorigenesis, and that overexpressed mIκBα may block IKKα anti-tumor activity. The K5 promoter is a very strong promoter to highly express the transgene in mice [24]. Thus, overexpression of mIκBα may have additional events beyond NF-κB pathways. Moreover, the overexpressed mIκBα has been shown to promote the development of SCC derived from activated HRAS SCC cells [68]. In contrast, overexpressed p65 or p50 increase cell senescence, suggesting that increased NF-κB inhibits skin SCC development, while decreased NF-κB promotes skin SCC development by regulating cell senescence [68]. The same mutations in the IκBα gene, which encodes IκBα, may not appear in human cancers (TCGA database). In general, NF-κB transcription factors regulate the expression of a broad spectrum of cytokines and chemokines that modulate tumor cell growth and survival and the tumor microenvironment. Some of IKKα’s targets share NF-κB’s pathways during inflammation and tumor development. We need to further reveal how IKKα regulates the expression of the inflammatory cytokines.

2.1.2. Lung SCC, Esophageal SCC, and Nasopharyngeal Carcinoma

The basal cells in the internal surface of lung air tubes, esophagi, and nasopharynges, which express K5/K14 and p63, are squamous-like epithelial cells. Like keratinocytes, these cells can be induced to differentiate and proliferate as well as give rise to well-differentiated papillomas and undifferentiated malignant carcinomas. IkkαKA/KA mice at six to 10 months of age on an FVB background develop spontaneous lung SCCs [22]. The IKKα levels in the lungs of IkkαKA/KA newborn pups are similar to WT. From four to 16 weeks of age, the IKKα levels are gradually decreased, which is associated with lung SCC development [22]. Reintroduced transgenic IKKα prevents lung SCC development. Thus, IKKα reduction promotes lung carcinogenesis. The mouse IkkαKA/KA lung SCCs express human lung SCC molecular traits, including reduced tumor suppressor p53 and Rb1, and overexpressed p63, Trim29, ROS1, Rhov, c-Myc, and stem cell markers. In addition, depleting macrophages prevents lung SCC development in this setting. Thus, the significantly increased number of infiltrating macrophages is essential for lung SCC development in IkkαKA/KA mice. We detected increased expression of TNFα, IL-1β, IL-6, IL-4, IL-13, CCL2, CXCL5, CXCL11, and CXCL8 in IkkαKA/KA lungs compared to WT lungs. These chemokines promote macrophage induction, migration, and recruitment [22,69,70]. Of note, these lung SCC and WT lungs express comparable p65 levels, suggesting that IKKα reduction does not downregulate NF-κB expression, though it is associated with marked expression of multiple cytokines, chemokines, and macrophage infiltration during lung SCC development.
The esophagus is one organ of the gastrointestinal tract, and it frequently has contact with environmental infectious agents. The immune system prevents bacterial and fungal colonization and expansion. Of interest, most esophageal SCCs (ESCCs) are found in China and South Asia, where the weather is humid and damp. Such an environment can foster fungal growth and contaminate food. We found that these human ESCCs are associated with increased fungal infection [23]. Defects in immunity or epithelial cells allow bacterial and fungal colonization in the oral and esophageal organs, promoting disease pathogenesis. IkkαKA/KA mice not only develop autoinflammation but show downregulated IL-17 expression in T cells in response to fungal stimulation [23]. IL-17 fights against fungal infection [71,72]. C57BL6 IkkαKA/KA mice showed increased fungal colonization in the oral cavity and esophagi, and approximatively 20% of five-month-old IkkαKA/KA mice develop spontaneous ESCC. Oral fungal inoculations promote ESCC incidence, while anti-fungal drug treatment decreases ESCC development in IkkαKA/KA mice [23]. Thus, increased fungal infection promotes ESCC development. These mouse ESCCs expressed reduced IKKα, p53, and p16 but increased EGFR activity and p63, which are the hallmarks for human ESCCs. They also express increased NF-κB1 and many cytokines and chemokines, including CCL7, CCL8, and IL-23, with infiltrating macrophages that express increased PD-L1, CXCL11, TNFα, and IL-6 [23]. Anti-fungal drug treatment decreased in infiltrating macrophage numbers and carcinogenesis. Overall, infection-mediated inflammation promotes esophageal carcinogenesis.
Nasopharyngeal carcinoma (NPC), which frequently occurs in Southeast Asia, is a deadly disease, because more than 95% of patients with NPC have type III undifferentiated carcinomas at first diagnosis [40]. NPC arises from the pharyngeal mucosal space and is associated with Epstein-Barr virus infection in most cases. Downregulated CHUK/IKKα expression is significantly correlated with aggressive and undifferentiated NPCs that express increased K13 and decreased vimentin [40]. IKKα deletion in human NPC cells promotes tumorigenesis, but reintroduced IKKα inhibits tumorigenesis derived from human NPC cells. EZH2 is identified as an inhibitor for downregulating IKKα expression via increasing the methylation on the Ikkα promoter. Also, decreased IKKα expression is correlated with increased ERK activity and expression of VEGF and MMP9 in these human NPCs. Whether IKKα reduction modulates the tumor microenvironment requires further investigation.

2.2. Adenocarcinoma

ADC is a type of cancer that originates from lung, pancreas, colon, prostate, or esophagus glands. The Cancer Genome Atlas (TCGA) database reveals activated KRAS mutations in approximately 35% of human lung ADCs, 90% of pancreatic ductal adenocarcinomas (PDACs), and 45% of colorectal ADCs (cBioPortal, Nature 2014, Nature 2016, and PanCancer Atlas). A high rate for activated KRAS mutations is a common feature for these different human ADCs.

2.2.1. Lung ADC

Lung ADC is derived from lung type II alveolar epithelial cells. CHUK nonsense mutations and homozygous/hemizygous deletions were found in human lung ADCs (cBioPortal, TCGA, Nature 2014) [38]. Patients with lung ADCs carrying double CHUK hemizygous deletions and KRAS mutations have significantly decreased survival rates compared to patients with KRAS mutations alone. Ikkα deletion specific in the lungs, induced by intratracheally injected adenovirus-Cre, causes spontaneous lung ADC development and promotes KrasG12D-initiated lung ADC development in KrasG12D;IkkαΔLU (Ikkα deletion in the lungs) mice (Table 3). Although the levels of NF-κB components are comparable in KrasG12D lung ADC and KrasG12D;IkkαΔLU ADCs, IKKα reduction in the lung ADCs elevated the expression of inflammatory cytokines and chemokines, including NF-κB targets [38]. Reintroducing IKKα into ADC cells suppressed tumor incidence and burden derived from the ADC cells in the lungs and repressed the expression of multiple cytokines, which indicates that impaired IKKα expression in cancer cells regulates the tumor microenvironment.
In addition, specifically induced Ikkα ablation in lung type II epithelial cells by Sftpc-CreERT2 promotes a carcinogen-initiated lung cancer development, but Ikkβ deletion inhibits lung ADC development in this setting (Table 3) [73]. We, like Chavdoula and colleagues, consistently demonstrated that IKKα deletion promotes the development of lung ADCs derived from a human ADC cell line, while reintroduced IKKα inhibits them [73]. Of note, p52 reduction inhibits lung tumorigenesis in the same setting [73]. These results suggest that NF-κB contributes to lung ADC development and that, during tumorigenesis, IKKα and NF-κB may function in two parallel pathways. Thus, the intriguing interplay between NF-κB and IKKα should be further investigated. Moreover, IKKβ depletion or NF-κB reduction inhibits lung epithelial cell proliferation and KrasG12D-mediated lung ADC development [75,76]. In contrast, another study reported an opposite finding in which deletion of Ikkα but not Ikkβ reduces KrasG12D-mediated lung ADC development through NF-κB activity [74], which is not supported by human TCGA data analyses [38].

2.2.2. Pancreatic ADC and Colorectal Carcinoma

Furthermore, patients with PADC carrying CHUK mutations have decreased survival rates (cBioPortal, Pancreas). Ikkα deletion in pancreatic cells mediated by Pdx1-Cre induces pancreatitis associated with the increased expression of TNFα, IL-1β, IL-6, MCP-1, and RANTES, which are NF-κB’s targets [77]. Patients with pancreatitis have increased incidence of pancreatic cancer. In addition, Ikkα deletion significantly promotes KrasG12D-innitiated PDAC development in mice (Table 3) [39]. Thus, IKKα reduction in pancreatic cells promotes inflammation associated with NF-κB targets.
Activated KRAS mutations are found in 40–50% of human colorectal carcinomas (cBioPortal, TCGA, Colorectal Adenocarcinoma cohorts). Meanwhile, the gut microbiota regulates carcinogenesis. In mouse models, chemical irritators and carcinogens have been broadly used for studying inflammation-associated colitis and carcinoma development. In this setting, Ikkα deletion in the intestinal epithelial cell (IEC) increases Citrobacter rodentium infection, and associated inflammation promotes DSS-mediated colitis [78]. Ikkα deletion in IEC cells recruits type III innate lymphocytes by elevating thymic stromal lymphopoietin to downregulate IL-22 in IkkαΔIEC mice. On the other hand, Ikkβ inactivation in IEC cells reduces colitis, which is the opposite of Ikkα ablation. This indicates IKKα and IKKβ have a distinct role in inflammation formation and colitis development [78]. Thus, IKKα prevents induced inflammation and is required for intestine-colon homeostasis in response to infectious and inflammatory stimuli. Interestingly, Nik deletion, as well as Ltbr deletion, increased inflammation in the colon following DSS treatment [79]. Therefore, the relationship of NIK, IKKα, and NF-κB in this setting needs further investigation.

2.3. Breast Cancer and Prostate Cancer

Breast and prostate cancers are related to hormone alterations. Interestingly, TCGA (cBioPortal, METABRIC, Nature 2012 & Nat Commun 2016) data analyses show that a proportion of these human cancers show increased or amplified cyclin D1, which is encoded by the CCND1 oncogenic gene. RANKL and RANK, the TNFR family members, regulate mammary gland development [80]. Consistently, kinase-inactive Ikkα knock-in (IkkαAA) mice, in which two serine residues were replaced by alanine residues at amino acid 177 and 181, show a defect in mammary gland development [34]. IkkαAA mammary epithelial lobuloalveolar cells reduced growth and NF-κB activity in response to RANKL but not TNFα treatment in a culture system [34]. Mammary tumorigenesis is inhibited in IkkαAA;Tg-MMTV.cyclin D1 mice as well as in Tg-MMTV.mIκBα mice compared to Tg-MMTV.cyclin D1 mice [34]. Thus, NF-κB is important for breast tumor development through RANKL/RANK/IKKα to the oncogene cyclin D1. Also, RANK/RANKL is involved in human breast cancer and has been used for therapeutic targets. The kinase-dead Ikkα knock-in (IkkαKA/KA) mice develop a more severe defect in the mammary gland compared to IkkαAA mice (unpublished data). In addition, the IkkαKA/KA female mice can have a single pregnancy with one or two babies and no milk production, and then these females because infertile (unpublished data). Whether an autoimmune condition contributes to this defect in reproductive organ development in IkkαKA/KA mice remains to be investigated [23]. Overall, IkkαAA mice and IkkαKA/KA mice share a common defect in mammary gland development, although these IkkαKA/KA mice develop additional spontaneous lung and skin SCC associated with IKKα reduction. Based on these results, the RANKL/RANK/IKKα pathway functions as a tumor promoter for the mammary gland cancer development.
TRAMP mice that overexpress SV40 in the prostate organ develop spontaneous prostate tumors [51]. The prostate tumorigenesis and metastasis were inhibited, which correlated with decreased expression of multiple cytokines, in IkkαAA;TRAMP male mice through a NF-κB RANK/ANKL pathway to regulate the expression of Maspin that is a tumor suppressor, compared to TRAMP transgenic mice [51]. This finding suggests that NF-κB may stimulate prostate cancer development. Interestingly, a PHLPP/FKBP51/IKKα complex has been reported to upregulate NF-κB and AKT activity in castration-resistant prostate cancer development [81], although the specific role of IKKα in this complex needs to be determined. In the future, the effect of cell-specific Ikkα deletion on breast and prostate cancer development should be investigated.

3. Conclusions

Overall, NF-κB and its targets intensify inflammation and accelerate SCC and ADC tumorigenesis. On the other hand, defective immunity-mediated systemic autoinflammation, initiated by germline IKK/NF-κB inactivation in the lymphoid organ, which cooperates with oncogenes or tumor suppressors, can also contribute to tumorigenesis. Thus, NF-κB can regulate tumorigenesis at different stages. IKKα reduction and ablation result in cutaneous, lung, oral, esophageal, nasopharyngeal, and pancreatic carcinogenesis associated with increased inflammation. IKKα inactivation–induced inflammation shows a similar pattern to that mediated by NF-κB activation. These findings will provide potential therapeutic targets for human cancer.
To date, most studies focus on IKKα, TNFR family members, and carcinogenesis. We still do not know about the crosstalk between IKKα-mediated pathways and Toll-like receptor pathways. Of note, the microbiota plays important roles in modulating inflammation and carcinogenesis. This may explain some contradictory results for IKK and NF-κB among different laboratories. In addition, we found that increased inflammation downregulates IKKα levels in tumors. Thus, the in vitro cultured cell lines may have higher IKKα levels than in vivo tumors. Furthermore, by western blotting, a non-specific band close beneath the IKKα band can mask a real IKKα protein band when IKKα levels are examined in mouse and human tissues, which may also contribute to the disagreements regarding IKKα expression among different laboratories.

Author Contributions

Conceptualization, X.L. and Y.H.; software, X.L.; writing—original draft preparation, X.L. and Y.H.; writing—review and editing, X.L. and Y.H.; funding acquisition, Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Cancer Institute (ZIA BC011212 and ZIA BC011212) to Y.H. This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

This research was funded by National Cancer Institute (ZIA BC011212 and ZIA BC011212) to Y.H.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hayden, M.S.; West, A.P.; Ghosh, S. NF-κB and the immune response. Oncogene 2006, 25, 6758–6780. [Google Scholar] [CrossRef] [Green Version]
  2. Xing, L.; Carlson, L.; Story, B.; Tai, Z.; Keng, P.; Siebenlist, U.; Boyce, B.F. Expression of either NF-κB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J. Bone Miner. Res. 2003, 18, 260–269. [Google Scholar] [CrossRef]
  3. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. Cell 2002, 109 (Suppl. 1), S81–S96. [Google Scholar] [CrossRef] [Green Version]
  4. Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017, 17, 545–558. [Google Scholar] [CrossRef]
  5. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krahn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C.; et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001, 293, 1495–1499. [Google Scholar] [CrossRef] [PubMed]
  6. Mock, B.A.; Connelly, M.A.; McBride, O.W.; Kozak, C.A.; Marcu, K.B. CHUK, a conserved helix-loop-helix ubiquitous kinase, maps to human chromosome 10 and mouse chromosome 19. Genomics 1995, 27, 348–351. [Google Scholar] [CrossRef] [PubMed]
  7. Connelly, M.A.; Marcu, K.B. CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain. Cell. Mol. Biol. Res. 1995, 41, 537–549. [Google Scholar] [PubMed]
  8. Zandi, E.; Rothwarf, D.M.; Delhase, M.; Hayakawa, M.; Karin, M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1997, 91, 243–252. [Google Scholar] [CrossRef] [Green Version]
  9. DiDonato, J.A.; Hayakawa, M.; Rothwarf, D.M.; Zandi, E.; Karin, M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997, 388, 548–554. [Google Scholar] [CrossRef]
  10. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; et al. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. Science 1997, 278, 860–866. [Google Scholar] [CrossRef]
  11. Hu, Y.; Baud, V.; Delhase, M.; Zhang, P.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999, 284, 316–320. [Google Scholar] [CrossRef] [PubMed]
  12. Doi, T.S.; Marino, M.W.; Takahashi, T.; Yoshida, T.; Sakakura, T.; Old, L.J.; Obata, Y. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc. Natl. Acad. Sci. USA 1999, 96, 2994–2999. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Makris, C.; Godfrey, V.L.; Krahn-Senftleben, G.; Takahashi, T.; Roberts, J.L.; Schwarz, T.; Feng, L.; Johnson, R.S.; Karin, M. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 2000, 5, 969–979. [Google Scholar] [CrossRef]
  14. Schmidt-Supprian, M.; Bloch, W.; Courtois, G.; Addicks, K.; Israel, A.; Rajewsky, K.; Pasparakis, M. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 2000, 5, 981–992. [Google Scholar] [CrossRef]
  15. Li, Q.; Van Antwerp, D.; Mercurio, F.; Lee, K.F.; Verma, I.M. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999, 284, 321–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Li, Z.W.; Chu, W.; Hu, Y.; Delhase, M.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. The IKKb subunit of IκB kinase (IKK) is essential for nuclear factor kB activation and prevention of apoptosis. J. Exp. Med. 1999, 189, 1839–1845. [Google Scholar] [CrossRef] [PubMed]
  17. Beg, A.A.; Sha, W.C.; Bronson, R.T.; Ghosh, S.; Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995, 376, 167–170. [Google Scholar] [CrossRef]
  18. Li, Q.; Lu, Q.; Hwang, J.Y.; Buscher, D.; Lee, K.F.; Izpisua-Belmonte, J.C.; Verma, I.M. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 1999, 13, 1322–1328. [Google Scholar] [CrossRef]
  19. Park, E.; Zhu, F.; Liu, B.; Xia, X.; Shen, J.; Bustos, T.; Fischer, S.M.; Hu, Y. Reduction in IκB kinase α expression promotes the development of skin papillomas and carcinomas. Cancer Res. 2007, 67, 9158–9168. [Google Scholar] [CrossRef] [Green Version]
  20. Van Hogerlinden, M.; Rozell, B.L.; Ahrlund-Richter, L.; Toftgard, R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res. 1999, 59, 3299–3303. [Google Scholar]
  21. Lind, M.H.; Rozell, B.; Wallin, R.P.; van Hogerlinden, M.; Ljunggren, H.G.; Toftgard, R.; Sur, I. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition. Proc. Natl. Acad. Sci. USA 2004, 101, 4972–4977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Xiao, Z.; Jiang, Q.; Willette-Brown, J.; Xi, S.; Zhu, F.; Burkett, S.; Back, T.; Song, N.Y.; Datla, M.; Sun, Z.; et al. The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell Carcinomas. Cancer Cell 2013, 23, 527–540. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Zhu, F.; Willette-Brown, J.; Song, N.Y.; Lomada, D.; Song, Y.; Xue, L.; Gray, Z.; Zhao, Z.; Davis, S.R.; Sun, Z.; et al. Autoreactive T Cells and Chronic Fungal Infection Drive Esophageal Carcinogenesis. Cell Host Microbe 2017, 21, 478–493. [Google Scholar] [CrossRef] [PubMed]
  24. Xia, X.; Park, E.; Liu, B.; Willette-Brown, J.; Gong, W.; Wang, J.; Mitchell, D.; Fischer, S.M.; Hu, Y. Reduction of IKKα expression promotes chronic ultraviolet B exposure-induced skin inflammation and carcinogenesis. Am. J. Pathol. 2010, 176, 2500–2508. [Google Scholar] [CrossRef] [PubMed]
  25. Page, A.; Navarro, M.; Garin, M.; Perez, P.; Casanova, M.L.; Moreno, R.; Jorcano, J.L.; Cascallana, J.L.; Bravo, A.; Ramirez, A. IKKβ leads to an inflammatory skin disease resembling interface dermatitis. J. Investig. Dermatol. 2010, 130, 1598–1610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Page, A.; Cascallana, J.L.; Casanova, M.L.; Navarro, M.; Alameda, J.P.; Perez, P.; Bravo, A.; Ramirez, A. IKKβ overexpression leads to pathologic lesions in stratified epithelia and exocrine glands and to tumoral transformation of oral epithelia. Mol. Cancer Res. 2011, 9, 1329–1338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Tetreault, M.P.; Weinblatt, D.; Ciolino, J.D.; Klein-Szanto, A.J.; Sackey, B.K.; Twyman-Saint Victor, C.; Karakasheva, T.; Teal, V.; Katz, J.P. Esophageal Expression of Active IκB Kinase-β in Mice Up-Regulates Tumor Necrosis Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Promoting Inflammation and Angiogenesis. Gastroenterology 2016, 150, 1609–1619.e11. [Google Scholar] [CrossRef] [Green Version]
  28. Klement, J.F.; Rice, N.R.; Car, B.D.; Abbondanzo, S.J.; Powers, G.D.; Bhatt, P.H.; Chen, C.H.; Rosen, C.A.; Stewart, C.L. IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 1996, 16, 2341–2349. [Google Scholar] [CrossRef] [Green Version]
  29. Lahtela, J.; Nousiainen, H.O.; Stefanovic, V.; Tallila, J.; Viskari, H.; Karikoski, R.; Gentile, M.; Saloranta, C.; Varilo, T.; Salonen, R.; et al. Mutant CHUK and severe fetal encasement malformation. N. Engl. J. Med. 2010, 363, 1631–1637. [Google Scholar] [CrossRef]
  30. Pannicke, U.; Baumann, B.; Fuchs, S.; Henneke, P.; Rensing-Ehl, A.; Rizzi, M.; Janda, A.; Hese, K.; Schlesier, M.; Holzmann, K.; et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N. Engl. J. Med. 2013, 369, 2504–2514. [Google Scholar] [CrossRef] [Green Version]
  31. Nielsen, C.; Jakobsen, M.A.; Larsen, M.J.; Muller, A.C.; Hansen, S.; Lillevang, S.T.; Fisker, N.; Barington, T. Immunodeficiency associated with a nonsense mutation of IKBKB. J. Clin. Immunol. 2014, 34, 916–921. [Google Scholar] [CrossRef]
  32. Mousallem, T.; Yang, J.; Urban, T.J.; Wang, H.; Adeli, M.; Parrott, R.E.; Roberts, J.L.; Goldstein, D.B.; Buckley, R.H.; Zhong, X.P. A nonsense mutation in IKBKB causes combined immunodeficiency. Blood 2014, 124, 2046–2050. [Google Scholar] [CrossRef]
  33. Burns, S.O.; Plagnol, V.; Gutierrez, B.M.; Al Zahrani, D.; Curtis, J.; Gaspar, M.; Hassan, A.; Jones, A.M.; Malone, M.; Rampling, D.; et al. Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKKβ. J. Allergy Clin. Immunol. 2014, 134, 215–218. [Google Scholar] [CrossRef] [Green Version]
  34. Cao, Y.; Bonizzi, G.; Seagroves, T.N.; Greten, F.R.; Johnson, R.; Schmidt, E.V.; Karin, M. IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001, 107, 763–775. [Google Scholar] [CrossRef] [Green Version]
  35. Maeda, G.; Chiba, T.; Kawashiri, S.; Satoh, T.; Imai, K. Epigenetic inactivation of IκB Kinase-α in oral carcinomas and tumor progression. Clin. Cancer Res. 2007, 13, 5041–5047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Descargues, P.; Sil, A.K.; Sano, Y.; Korchynskyi, O.; Han, G.; Owens, P.; Wang, X.J.; Karin, M. IKKα is a critical coregulator of a Smad4-independent TGFβ-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 2008, 105, 2487–2492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Liu, B.; Xia, X.; Zhu, F.; Park, E.; Carbajal, S.; Kiguchi, K.; DiGiovanni, J.; Fischer, S.M.; Hu, Y. IKKα is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell 2008, 14, 212–225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Song, N.Y.; Zhu, F.; Wang, Z.; Willette-Brown, J.; Xi, S.; Sun, Z.; Su, L.; Wu, X.; Ma, B.; Nussinov, R.; et al. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways. Proc. Natl. Acad. Sci. USA 2018, 115, E812–E821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Todoric, J.; Antonucci, L.; Di Caro, G.; Li, N.; Wu, X.; Lytle, N.K.; Dhar, D.; Banerjee, S.; Fagman, J.B.; Browne, C.D.; et al. Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell 2017, 32, 824–839.e8. [Google Scholar] [CrossRef] [Green Version]
  40. Yan, M.; Zhang, Y.; He, B.; Xiang, J.; Wang, Z.F.; Zheng, F.M.; Xu, J.; Chen, M.Y.; Zhu, Y.L.; Wen, H.J.; et al. IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat. Commun. 2014, 5, 3661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Hu, Y.; Baud, V.; Oga, T.; Kim, K.I.; Yoshida, K.; Karin, M. IKKα controls formation of the epidermis independently of NF-κB. Nature 2001, 410, 710–714. [Google Scholar] [CrossRef]
  42. Lee, J.C.; Kundu, J.K.; Hwang, D.M.; Na, H.K.; Surh, Y.J. Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-κB and AP-1: IκB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 2007, 28, 1491–1498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Martin, B.N.; Wang, C.; Willette-Brown, J.; Herjan, T.; Gulen, M.F.; Zhou, H.; Bulek, K.; Franchi, L.; Sato, T.; Alnemri, E.S.; et al. IKKα negatively regulates ASC-dependent inflammasome activation. Nat. Commun. 2014, 5, 4977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Lawrence, T.; Bebien, M.; Liu, G.Y.; Nizet, V.; Karin, M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 2005, 434, 1138–1143. [Google Scholar] [CrossRef] [PubMed]
  45. Pelzer, C.; Thome, M. IKKα takes control of canonical NF-κB activation. Nat. Immunol. 2011, 12, 815–816. [Google Scholar] [CrossRef] [PubMed]
  46. Shembade, N.; Pujari, R.; Harhaj, N.S.; Abbott, D.W.; Harhaj, E.W. The kinase IKKα inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1. Nat. Immunol. 2011, 12, 834–843. [Google Scholar] [CrossRef] [Green Version]
  47. Pasparakis, M.; Courtois, G.; Hafner, M.; Schmidt-Supprian, M.; Nenci, A.; Toksoy, A.; Krampert, M.; Goebeler, M.; Gillitzer, R.; Israel, A.; et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002, 417, 861–866. [Google Scholar] [CrossRef]
  48. Nenci, A.; Huth, M.; Funteh, A.; Schmidt-Supprian, M.; Bloch, W.; Metzger, D.; Chambon, P.; Rajewsky, K.; Krieg, T.; Haase, I.; et al. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum. Mol. Genet. 2006, 15, 531–542. [Google Scholar] [CrossRef]
  49. Stratis, A.; Pasparakis, M.; Rupec, R.A.; Markur, D.; Hartmann, K.; Scharffetter-Kochanek, K.; Peters, T.; van Rooijen, N.; Krieg, T.; Haase, I. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Investig. 2006, 116, 2094–2104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Rebholz, B.; Haase, I.; Eckelt, B.; Paxian, S.; Flaig, M.J.; Ghoreschi, K.; Nedospasov, S.A.; Mailhammer, R.; Debey-Pascher, S.; Schultze, J.L.; et al. Crosstalk between keratinocytes and adaptive immune cells in an IκBα protein-mediated inflammatory disease of the skin. Immunity 2007, 27, 296–307. [Google Scholar] [CrossRef] [Green Version]
  51. Luo, J.L.; Tan, W.; Ricono, J.M.; Korchynskyi, O.; Zhang, M.; Gonias, S.L.; Cheresh, D.A.; Karin, M. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446, 690–694. [Google Scholar] [CrossRef] [PubMed]
  52. Liu, B.; Park, E.; Zhu, F.; Bustos, T.; Liu, J.; Shen, J.; Fischer, S.M.; Hu, Y. A critical role for IκB kinase α in the development of human and mouse squamous cell carcinomas. Proc. Natl. Acad. Sci. USA 2006, 103, 17202–17207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Liu, B.; Willette-Brown, J.; Liu, S.; Chen, X.; Fischer, S.M.; Hu, Y. IKKα represses a network of inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a dose-dependent manner in the skin. Cell Death Differ. 2011, 18, 1854–1864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Kumari, S.; Bonnet, M.C.; Ulvmar, M.H.; Wolk, K.; Karagianni, N.; Witte, E.; Uthoff-Hachenberg, C.; Renauld, J.C.; Kollias, G.; Toftgard, R.; et al. Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity 2013, 39, 899–911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Moore, R.J.; Owens, D.M.; Stamp, G.; Arnott, C.; Burke, F.; East, N.; Holdsworth, H.; Turner, L.; Rollins, B.; Pasparakis, M.; et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat. Med. 1999, 5, 828–831. [Google Scholar] [CrossRef] [PubMed]
  56. Suganuma, M.; Okabe, S.; Marino, M.W.; Sakai, A.; Sueoka, E.; Fujiki, H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999, 59, 4516–4518. [Google Scholar] [PubMed]
  57. Akiyama, T.; Shimo, Y.; Yanai, H.; Qin, J.; Ohshima, D.; Maruyama, Y.; Asaumi, Y.; Kitazawa, J.; Takayanagi, H.; Penninger, J.M.; et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008, 29, 423–437. [Google Scholar] [CrossRef] [Green Version]
  58. Boehm, T.; Scheu, S.; Pfeffer, K.; Bleul, C.C. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTβR. J. Exp. Med. 2003, 198, 757–769. [Google Scholar] [CrossRef] [Green Version]
  59. Seach, N.; Ueno, T.; Fletcher, A.L.; Lowen, T.; Mattesich, M.; Engwerda, C.R.; Scott, H.S.; Ware, C.F.; Chidgey, A.P.; Gray, D.H.; et al. The lymphotoxin pathway regulates Aire-independent expression of ectopic genes and chemokines in thymic stromal cells. J. Immunol. 2008, 180, 5384–5392. [Google Scholar] [CrossRef]
  60. Kajiura, F.; Sun, S.; Nomura, T.; Izumi, K.; Ueno, T.; Bando, Y.; Kuroda, N.; Han, H.; Li, Y.; Matsushima, A.; et al. NF-κB-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J. Immunol. 2004, 172, 2067–2075. [Google Scholar] [CrossRef] [Green Version]
  61. Burkly, L.; Hession, C.; Ogata, L.; Reilly, C.; Marconi, L.A.; Olson, D.; Tizard, R.; Cate, R.; Lo, D. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995, 373, 531–536. [Google Scholar] [CrossRef]
  62. Weih, F.; Carrasco, D.; Durham, S.K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S.A.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995, 80, 331–340. [Google Scholar] [CrossRef] [Green Version]
  63. Kinoshita, D.; Hirota, F.; Kaisho, T.; Kasai, M.; Izumi, K.; Bando, Y.; Mouri, Y.; Matsushima, A.; Niki, S.; Han, H.; et al. Essential role of IκB kinase α in thymic organogenesis required for the establishment of self-tolerance. J. Immunol. 2006, 176, 3995–4002. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Lomada, D.; Liu, B.; Coghlan, L.; Hu, Y.; Richie, E.R. Thymus Medulla Formation and Central Tolerance Are Restored in IKKα−/− Mice That Express an IKKα Transgene in Keratin 5+ Thymic Epithelial Cells. J. Immunol. 2007, 178, 829–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Mathis, D.; Benoist, C. Aire. Annu. Rev. Immunol. 2009, 27, 287–312. [Google Scholar] [CrossRef] [PubMed]
  66. Zhu, F.; Willette-Brown, J.; Zhang, J.; Ferre, E.M.N.; Sun, Z.; Wu, X.; Lionakis, M.S.; Hu, Y. NLRP3 Inhibition Ameliorates Severe Cutaneous Autoimmune Manifestations in a Mouse Model of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-Like Disease. J. Investig. Dermatol. 2020. [Google Scholar] [CrossRef]
  67. Zhu, F.; Hu, Y. Integrity of IKK/NF-κB Shields Thymic Stroma That Suppresses Susceptibility to Autoimmunity, Fungal Infection, and Carcinogenesis. Bioessays 2018, 40, e1700131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Dajee, M.; Lazarov, M.; Zhang, J.Y.; Cai, T.; Green, C.L.; Russell, A.J.; Marinkovich, M.P.; Tao, S.; Lin, Q.; Kubo, Y.; et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003, 421, 639–643. [Google Scholar] [CrossRef] [PubMed]
  69. Wang, X.; Gray, Z.; Willette-Brown, J.; Zhu, F.; Shi, G.; Jiang, Q.; Song, N.Y.; Dong, L.; Hu, Y. Macrophage inducible nitric oxide synthase circulates inflammation and promotes lung carcinogenesis. Cell Death Discov. 2018, 4, 46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Gray, Z.; Shi, G.; Wang, X.; Hu, Y. Macrophage inducible nitric oxide synthase promotes the initiation of lung squamous cell carcinoma by maintaining circulated inflammation. Cell Death Dis. 2018, 9, 642. [Google Scholar] [CrossRef] [PubMed]
  71. Puel, A.; Cypowyj, S.; Bustamante, J.; Wright, J.F.; Liu, L.; Lim, H.K.; Migaud, M.; Israel, L.; Chrabieh, M.; Audry, M.; et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332, 65–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Dominguez-Villar, M.; Hafler, D.A. Immunology. An innate role for IL-17. Science 2011, 332, 47–48. [Google Scholar] [CrossRef] [PubMed]
  73. Chavdoula, E.; Habiel, D.M.; Roupakia, E.; Markopoulos, G.S.; Vasilaki, E.; Kokkalis, A.; Polyzos, A.P.; Boleti, H.; Thanos, D.; Klinakis, A.; et al. CHUK/IKK-α loss in lung epithelial cells enhances NSCLC growth associated with HIF up-regulation. Life Sci. Alliance 2019, 2, e201900460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Vreka, M.; Lilis, I.; Papageorgopoulou, M.; Giotopoulou, G.A.; Lianou, M.; Giopanou, I.; Kanellakis, N.I.; Spella, M.; Agalioti, T.; Armenis, V.; et al. IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2018, 78, 2939–2951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Xia, Y.; Yeddula, N.; Leblanc, M.; Ke, E.; Zhang, Y.; Oldfield, E.; Shaw, R.J.; Verma, I.M. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 2012, 14, 257–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Meylan, E.; Dooley, A.L.; Feldser, D.M.; Shen, L.; Turk, E.; Ouyang, C.; Jacks, T. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462, 104–107. [Google Scholar] [CrossRef] [PubMed]
  77. Li, N.; Wu, X.; Holzer, R.G.; Lee, J.H.; Todoric, J.; Park, E.J.; Ogata, H.; Gukovskaya, A.S.; Gukovsky, I.; Pizzo, D.P.; et al. Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice. J. Clin. Investig. 2013, 123, 2231–2243. [Google Scholar] [CrossRef] [Green Version]
  78. Giacomin, P.R.; Moy, R.H.; Noti, M.; Osborne, L.C.; Siracusa, M.C.; Alenghat, T.; Liu, B.; McCorkell, K.A.; Troy, A.E.; Rak, G.D.; et al. Epithelial-intrinsic IKKα expression regulates group 3 innate lymphoid cell responses and antibacterial immunity. J. Exp. Med. 2015, 212, 1513–1528. [Google Scholar] [CrossRef] [Green Version]
  79. Ramakrishnan, S.K.; Zhang, H.; Ma, X.; Jung, I.; Schwartz, A.J.; Triner, D.; Devenport, S.N.; Das, N.K.; Xue, X.; Zeng, M.Y.; et al. Intestinal non-canonical NFκB signaling shapes the local and systemic immune response. Nat. Commun. 2019, 10, 660. [Google Scholar] [CrossRef] [Green Version]
  80. Kiesel, L.; Kohl, A. Role of the RANK/RANKL pathway in breast cancer. Maturitas 2016, 86, 10–16. [Google Scholar] [CrossRef]
  81. Shang, Z.; Yu, J.; Sun, L.; Tian, J.; Zhu, S.; Zhang, B.; Dong, Q.; Jiang, N.; Flores-Morales, A.; Chang, C.; et al. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex. Nucleic Acids Res. 2019, 47, 4211–4225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cancers 13 01411 g001 550
Figure 1. A model of canonical and non-canonical NF-κB pathways. (aa: amino acid; two IKKα molecules form a homodimer in the non-canonical NF-κB pathway).
Figure 1. A model of canonical and non-canonical NF-κB pathways. (aa: amino acid; two IKKα molecules form a homodimer in the non-canonical NF-κB pathway).
Cancers 13 01411 g001
Table
Table 1. Comparison of physiological activities and IKK/NF-κB activities in genetically modified mice and humans.
Table 1. Comparison of physiological activities and IKK/NF-κB activities in genetically modified mice and humans.
MiceDevelopmental PhenotypesTnfr1 KO/NF-κBTumorigenesisReferences
Ikkα−/−Die soon after birth, marked epidermal hyperplasiaTnfr1 KO does not rescue mutants; slightly reduced or increased NF-κB activityIkkα+/− mice develop carcinogen-induced skin carcinogenesis [11,18,19]
Ikkβ−/−Embryonic lethality, liver cell apoptosis, hemorrhageTnfr1 KO rescues mutants,
blocks NF-κB activity		Not tested[15,16]
Ikkγ−/−Embryonic lethality, liver cell apoptosis, hemorrhageTnfr1 KO rescues mutants,
blocks NF-κB activity		Not tested[13,14]
p65(Rela)−/−Embryonic lethality, liver cell apoptosis, hemorrhageTnfr1 KO rescues mutants,
blocks NF-κB activity		Not tested[12,17]
Tg-K5.mIκBαNormal embryonic development;
skin phenotypes with cell apoptosis and inflammation		Tnfr1 KO rescues mutantsSpontaneous skin tumors[20,21]
Tg-K5.IKKαNormal mice and normal skin from one day to more than one yearNot tested for Tnfr1 KO;
no increase in skin NF-κB 		Inhibit UVB-induced skin
carcinogenesis; rescue lung squamous cell carcinomas and autoimmunity		[22,23,24]
Tg-IKKβNormal embryonic developmentNot tested for Tnfr1 KO;
increased NF-κB activity		Epidermal hyperplasia and spontaneous oral tumors [25,26]
Tg-EDL2.IKKβNormal embryonic developmentNot tested for Tnfr1 KO;
increased NF-κB activity		Esophageal hyperplasia[27]
Iκbα−/−Die within 6 weeks after birth with severe skin inflammation Not tested for Tnfr1 KO;
increased NF-κB activity		Not tested[28]
Human CHUK
mutations		Mutations at amino acid 422 to generate a stop code; embryonic lethality at 12–14 weeks Appearance like Ikkα−/− mice; defects in the face, limbs, kidneys, heart, lungs, boneGene mutations and deletions associated with reduced survival of lung adenocarcinoma patients [29]
Human IKBKB
mutations		Infants and children with IKBKB mutations show severe infectionReduced NF-κB activityDetected mutations but not known for lung cancer survival [30,31,32,33]
Table
Table 2. Comparison of physiological activities and tumorigenesis in mice lacking IKK/NF-kB in specific tissues.
Table 2. Comparison of physiological activities and tumorigenesis in mice lacking IKK/NF-kB in specific tissues.
MiceNeonatal PhenotypesTnfr1 KO/NF-κBTumorigenesisReferences
Ikkαf/f;K5.CreDie within 3 weeks; neonatal epidermal hyperplasia and severe inflammationTnfr1 KO does not rescue mutants; increased TNF and NF-κBNA[37]
Ikkαf/f;K14.CreDie within 3 weeks; neonatal epidermal hyperplasia and severe inflammationNot rescuedNA[37]
Ikkβf/f;K14.CreDie within 3 weeks; neonatal epidermal hyperplasia and severe inflammationTnfr1 KO rescues mutants and skin lesionsNA[47]
Ikkγf/f;K14.CreDie within 3 weeks; neonatal epidermal hyperplasia and severe inflammationTnfr1 KO rescues mutants and skin lesionsNA[48]
Ikkαf/f;K5.CreERSkin inflammation, hairless, and spontaneous skin tumors Not tested for Tnfr1 KO; Egfr+/− and EGFR inhibitor rescue Egfr+/− and EGFR inhibitor prevent skin tumorigenesis [37]
Ikkαf/f;K15.CreRP1Skin inflammation, hairless, and spontaneous skin tumors Not tested for Tnfr1 KOEGFR inhibitor prevents skin tumorigenesis[37]
Ikkβf/f;K14.CreERSkin inflammation in some mice at 3⎯6 months of ageAnti-TNFR1 antibody rescues skin lesionsNo skin tumors reported[49]
Ikkγf/f;K14.CreERNo severe skin phenotypes Not tested for Tnfr1 KONo skin tumors reported[48]
p65(Rela)f/f;K5.CreNo severe skin phenotypesNot tested for Tnfr1 KONo skin tumors reported[50]
Iκbαf/f;K5.CreSkin inflammationTnf KO/LTβ KO rescues skin phenotypes; increased NF-κB No skin tumors reported[50]
IkkαAA/AA: mutations
177/181-Ser/Allan		Defects in mammary gland development through reducing RANKL/RANK, normal skin Not tested for Tnfr1 KOReduced breast and prostate cancer[34,51]
IkkαKA/KA: mutations
44-Lys/Allan		Defects in central tolerance, autoimmunity, and mammary glands Unpublished data: Tnfr1 KO partially reduces skin phenotypesSpontaneous skin, lung, and esophageal tumors correlated with decreased IKKα levels[22,23]
Table
Table 3. Impact of IKK/NF-κB activities in lung and pancreatic adenocarcinomas (ADCs).
Table 3. Impact of IKK/NF-κB activities in lung and pancreatic adenocarcinomas (ADCs).
MiceTumorigenesisNF-κB activityReferences
Ikkαf/f;Ad.Cre-intratrachealSpontaneous lung ADC;
promoted KrasG12D-mediated lung ADC		Similar NF-κB activity in these ADCs from different groups [38]
Ikkαf/f;Sftpc.CreERPromoted carcinogen-induced lung ADC developmentp52 reduction inhibited ADC development derived from human ADC cells[73]
Ikkαf/f;Sftpc.Cre or Scgb1a1.CreInhibited KrasG12D-mediated lung ADC development Reduced NF-κB activity[74]
Ikkαf/f;Pdx-1.CrePromoted KrasG12D-mediated pancreatic carcinoma Not tested[39]
IKKβ depletionInhibited lung epithelial proliferation and KrasG12D-mediated lung ADCsInhibited NF-κB activity[75,76]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Li, X.; Hu, Y. Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis. Cancers 2021, 13, 1411. https://doi.org/10.3390/cancers13061411

AMA Style

Li X, Hu Y. Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis. Cancers. 2021; 13(6):1411. https://doi.org/10.3390/cancers13061411

Chicago/Turabian Style

Li, Xin, and Yinling Hu. 2021. "Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis" Cancers 13, no. 6: 1411. https://doi.org/10.3390/cancers13061411

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop